Voyageur Pharmaceuticals Appoints Wall Street Veteran Virginia Alling to Board to Drive U.S. Market Expansion

Voyageur Pharmaceuticals Ltd. has appointed Virginia Alling as an independent director, subject to regulatory approval, marking the company's latest strategic move to enhance its board with Wall Street expertise for U.S. market expansion. This appointment follows recent additions of Jeffrey J. Kraws and Christopher A. Van Buren, creating a board with substantial financial market experience to support the company's North American growth ambitions.

Alling brings over 30 years of experience in corporate banking, capital markets, and strategic advisory for both privately held and publicly traded companies. As Senior Vice President & Managing Director at PNC Bank in East Brunswick, NJ, she manages a multi-billion-dollar portfolio of corporate clients in New Jersey and New York, with expertise spanning mergers and acquisitions, initial public offerings, employee stock ownership plans, leveraged finance, and revenue optimization. Her background includes previous roles at JPMorgan Chase and Wells Fargo, and she holds an MBA from the Raymond A. Mason School of Business at the College of William & Mary.

Brent Willis, Voyageur's CEO, stated that Alling's track record in executing U.S. public offerings, revenue optimization, and cross-border financing complements the company's recent board appointments. He emphasized that her deep experience in M&A and capital markets will be instrumental in unlocking institutional U.S. investment and streamlining the company's U.S. market entry. Willis noted that her expertise in family-owned enterprises and strategic partnerships aligns with Voyageur's vision of sustainable growth and value creation for shareholders.

The collective experience of Alling, Kraws, and Van Buren underscores Voyageur's commitment to assembling a high-caliber board with proven Wall Street acumen to facilitate U.S. market expansion. Their expertise in revenue generation, IPO execution, and regulatory compliance is expected to support Voyageur's commercialization efforts, including FDA approvals for its barium contrast products and scaling of its Oklahoma iodine operations. The company aims to become a key player in the vertically integrated barium and iodine contrast markets, controlling all primary input costs from raw material sourcing to final production.

Voyageur's business strategy involves generating sales by partnering with established third-party GMP pharmaceutical manufacturers in Canada to validate its products by regulatory agencies worldwide. The company owns a 100% interest in the Frances Creek barium sulphate project, which contains rare, high-grade mineral suitable for pharmaceutical applications. Voyageur believes this natural mineral will replace current synthetic barium sulphate products in the pharmaceutical marketplace with higher quality imaging products. More information about the company can be found at https://voyageurpharmaceuticals.ca.